Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1893 1
1961 1
1962 1
1964 1
1974 1
1975 1
1977 1
1979 5
1980 4
1981 1
1982 7
1983 1
1984 4
1985 1
1986 6
1987 8
1988 5
1989 4
1990 9
1991 9
1992 5
1993 7
1994 5
1995 3
1996 12
1997 12
1998 6
1999 13
2000 14
2001 22
2002 17
2003 9
2004 14
2005 16
2006 17
2007 13
2008 13
2009 23
2010 26
2011 12
2012 13
2013 10
2014 5
2015 7
2016 5
2017 11
2018 10
2019 6
2020 10
2021 2
2022 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. Pardanani A, et al. Among authors: milligan d. JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590. JAMA Oncol. 2015. PMID: 26181658 Clinical Trial.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. Lancet Oncol. 2011. PMID: 21940214 Clinical Trial.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
Levosimendan: calcium sensitizer and inodilator.
Milligan DJ, Fields AM. Milligan DJ, et al. Anesthesiol Clin. 2010 Dec;28(4):753-60. doi: 10.1016/j.anclin.2010.08.003. Anesthesiol Clin. 2010. PMID: 21074750 Review.
Moya moya vasculopathy and MECP2 duplication syndrome.
Holover G, Adams D, Milligan D, Goldberg R, Rios J, Kornitzer J, Mazzola C. Holover G, et al. Among authors: milligan d. Childs Nerv Syst. 2024 Mar;40(3):809-812. doi: 10.1007/s00381-023-06139-0. Epub 2023 Oct 7. Childs Nerv Syst. 2024. PMID: 37804337 Review.
383 results